No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - The share price of ECO Animal Health surged on Monday after European regulators recommended marketing authorisation for its poultry vaccine ECOVAXXIN MS.
The AIM-listed company, which focuses on treatments for respiratory and enteric diseases in pigs and poultry, said the key milestone now establishes a roadmap for the commercial launch of the drug in the second half of 2026.
ECOVAXXIN MS is an immunisation against mycoplasma synoviae, which can cause air-sac and foot-pad lesions in poultry, which can result in a 5-10% reduction in the number of eggs laid by affected hens.
David Hallas, chief executive of ECO Animal Health, said he was "delighted" by the announcement from the the Committee for Medicinal Products for Veterinary Use of the European Medicines Agency.
"This marks an exciting time for the company, with further submissions expected over the next 12 months for additional products from our R&D pipeline, underpinning ECO's next phase of growth."
The stock was up 8.4% at 87.8p by 1136 GMT.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.